Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025
Investors eyeing high-growth stocks should consider Corcept Therapeutics, TKO Group, and others with strong earnings ...
HHS increasing scrutiny of vaccines under RFK Jr., WSJ reports
The Health and Human Services Department is reviewing contracts and moving to replace vaccine advisers in Robert F. Kennedy Jr.’s first few ...
Lawyer Monthly4h
Gilead Sciences Sets Aside $200M for HIV Drug Settlement
Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal investigation.
Medical Stocks To Consider – March 2nd
Eli Lilly and Company, UnitedHealth Group, AbbVie, Walmart, Johnson & Johnson, Natera, and Gilead Sciences are the seven Medical stocks to watch today, according to MarketBeat’s stock screener tool.
Hosted on MSN14h
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
In the latest market close, Gilead Sciences (GILD) reached $115.99, with a +1.47% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 1.76%. Meanwhile, the Dow ...
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
Gilead Sciences sets aside $200 million to resolve HIV drug probe
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...